The estimated Net Worth of Peter Linde is at least $1.17 Milhão dollars as of 16 September 2021. Peter Linde owns over 10,378 units of Morphic Inc stock worth over $870,351 and over the last 5 years he sold MORF stock worth over $299,100. In addition, he makes $0 as Chief Medical Officer at Morphic Inc.
Peter has made over 3 trades of the Morphic Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 10,378 units of MORF stock worth $591,442 on 16 September 2021.
The largest trade he's ever made was exercising 21,743 units of Morphic Inc stock on 16 March 2021 worth over $1,239,134. On average, Peter trades about 7,624 units every 37 days since 2020. As of 16 September 2021 he still owns at least 15,272 units of Morphic Inc stock.
You can see the complete history of Peter Linde stock trades at the bottom of the page.
Dr. Peter G. Linde M.D. serves as Chief Medical Officer of the Company. He has served as Vice President of medical research at Acceleron Pharma, Inc. since July 2016. Prior to Acceleron, Dr. Linde served as Global Project Leader, Development at AbbVie Inc. from September 2011 to June 2016 and as Senior Director of Clinical Research at FibroGen, Inc. from 2010 to 2011. Prior to this, Dr. Linde served as Co-Founder and President of Triaxis Medical Devices, Inc., a medical device company, from 2008 to 2010. Dr. Linde received his bachelor’s degree in Chemical Engineering and Applied Biology from the Massachusetts Institute of Technology and his Medical Doctorate from Stanford University School of Medicine.
Peter Linde is 53, he's been the Chief Medical Officer of Morphic Inc since 2020. There are 6 older and 12 younger executives at Morphic Inc. The oldest executive at Morphic Holding Inc is Dr. Timothy A. Springer Ph.D., 73, who is the Founder, Independent Director & Member of Scientific Advisory Board.
Peter's mailing address filed with the SEC is C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM, MA, 02451.
Over the last 5 years, insiders at Morphic Inc have traded over $69,316,197 worth of Morphic Inc stock and bought 3,360,997 units worth $101,882,696 . The most active insiders traders include Plc Gsk, Holdings A/S Novo, eTimothy A Springer. On average, Morphic Inc executives and independent directors trade stock every 13 days with the average trade being worth of $2,254,353. The most recent stock trade was executed by Bruce Rogers on 8 July 2024, trading 20,000 units of MORF stock currently worth $86,400.
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
Morphic Inc executives and other stock owners filed with the SEC include: